Yemaachi, a Ghanaian cancer diagnostics and research company completes $3 million in a seed round
Yemaachi Biotech, a Ghanaian cancer research and diagnostics company, has raised $3 million in a seed round to advance its goal of global precision oncology diversification.
V8 Capital led the round, which included LifeLine Family Heritage Fund, Y Combinator, Tencent, LoftyInc Capital, VestedWorld, V Square Capital, and Ethan Perlstein.
In January, the company launched its at-home Sheba HPV Test in Ghana to help identify women at high risk of cervical cancer, which is the second most common malignancy among women in West Africa.
Yemaachi Biotechnology, founded in 2020, uses cutting-edge immunogenomics, bioinformatics, and artificial intelligence to accelerate the development of cancer detection and cure solutions, reducing the economic burden of cancer.
“Creating the most genetically diverse dataset can enable rapid discoveries with long-term implications for cancer research, medication development, and patient care, not only in Africa but globally,” said Yaw Bediako, Ph.D., co-founder and CEO of Yemaachi.
The company has already made strides with its unique diagnostics and partnerships.
Yemaachi and Lucence launched the AMBER Study late last year, using liquid biopsy to better describe and understand the genetics of breast cancer in women of African descent.
The Bill and Melinda Gates Foundation has given Yemaachi a $1 million grant as part of Bediako’s Calestous Juma Science Leadership Fellowship.
